Solid Tumor – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Solid Tumor - Pipeline Review, H1 2012', provides an overview of the Solid Tumor therapeutic pipeline. This report provides information on the therapeutic development for Solid Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Solid Tumor. 'Solid Tumor - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Solid Tumor.
- A review of the Solid Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Solid Tumor pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Solid Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Solid Tumor pipeline depth and focus of Solid Tumor therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 11
List of Figures 21
Introduction 22
Global Markets Direct Report Coverage 22
Solid Tumor Overview 23
Therapeutics Development 24
An Overview of Pipeline Products for Solid Tumor 24
Solid Tumor Therapeutics under Development by Companies 26
Solid Tumor Therapeutics under Investigation by Universities/Institutes 47
Late Stage Products 60
Comparative Analysis 60
Mid Clinical Stage Products 61
Comparative Analysis 61
Early Clinical Stage Products 62
Comparative Analysis 62
Discovery and Pre-Clinical Stage Products 63
Comparative Analysis 63
Solid Tumor Therapeutics – Products under Development by Companies 64
Solid Tumor Therapeutics – Products under Investigation by Universities/Institutes 117
Companies Involved in Solid Tumor Therapeutics Development 166
Bristol-Myers Squibb Company 166
Genzyme Corporation 167
Johnson & Johnson 168
Boehringer Ingelheim GmbH 169
F. Hoffmann-La Roche Ltd. 170
Kyowa Hakko Kirin Co., Ltd. 171
Abbott Laboratories 172
Biogen Idec Inc. 173
Shionogi & Co., Ltd. 174
Amgen Inc. 175
Sanofi-Aventis 176
Adherex Technologies Inc. 177
AstraZeneca PLC 178
Eli Lilly and Company 179
GlaxoSmithKline plc 180
Seattle Genetics, Inc. 181
Tekmira Pharmaceuticals Corp. 182
Genentech, Inc. 183
Nektar Therapeutics 185
MedImmune LLC 186
Gilead Sciences, Inc. 187
Errant Gene Therapeutics, LLC 422
Mebiopharm Co., Ltd. 423
IkerChem S.L. 424
Agennix AG 425
ImQuest Life Sciences 426
Solid Tumor – Therapeutics Assessment 427
Assessment by Monotherapy Products 427
Assessment by Combination Products 428
Assessment by Route of Administration 429
Assessment by Molecule Type 432
Drug Profiles 435
Eniluracil - Drug Profile 435
IMC-1121B - Drug Profile 437
Exelbine - Drug Profile 439
YN968D1 - Drug Profile 441
Alpha-Lipoic Acid - Drug Profile 442
memantine hydrochloride - Drug Profile 444
Cefazolin - Drug Profile 445
Ondansetron - Drug Profile 446
Levofloxacin - Drug Profile 447
Lamotrigine - Drug Profile 448
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile 449
cefazolin Sodium - Drug Profile 450
Dexamethason + Metoclopramide - Drug Profile 451
Dexamethasone + Dronabinol + Palonosetron hydrochloride - Drug Profile 452
Dexamethasone + Gabapentin - Drug Profile 454
Dexamethasone + Granisetron - Drug Profile 456
Dexamethasone + Granisetron Hydrochloride + Metoclopramide Hydrochloride - Drug Profile 457
Cyclophosphamide + Total Body Irradiation - Drug Profile 459
octreotide acetate - Drug Profile 461
Oxandrolone - Drug Profile 462
Solid Tumor Therapeutics – Drug Profile Updates 463
Solid Tumor Therapeutics – Discontinued Products 465
Solid Tumor Therapeutics - Dormant Products 479
Solid Tumor – Product Development Milestones 525
Featured News & Press Releases 525
Jan 12, 2012: Synta Pharmaceuticals And University Of Toronto Researchers Elucidate Elesclomol Mechanism Of Action Using Innovative Yeast-Based Technology 525
Jan 11, 2012: Merrimack Pharmaceuticals Initiates Enrollment In Phase I Study Of MM-151 In Patients With Refractory Advanced Solid Tumors 526
Jan 03, 2012: Marshall Edwards Receives New Method Of Use Patent For Lead Oncology Drug Candidate ME-344 526
Appendix 531
Methodology 531
Coverage 531
Secondary Research 531
Primary Research 531
Expert Panel Validation 532
Contact Us 532
Disclaimer 532
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Solid Tumor, H1 2012 24
Products under Development for Solid Tumor – Comparative Analysis, H1 2012 25
Number of Products under Development by Companies, H1 2012 27
Number of Products under Investigation by Universities/Institutes, H1 2012 48
Comparative Analysis by Late Stage Development, H1 2012 60
Comparative Analysis by Mid Clinical Stage Development, H1 2012 61
Comparative Analysis by Early Clinical Stage Development, H1 2012 62
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 63
Products under Development by Companies, H1 2012 64
Products under Investigation by Universities/Institutes, H1 2012 117
Bristol-Myers Squibb Company, H1 2012 166
Genzyme Corporation, H1 2012 167
Johnson & Johnson, H1 2012 168
Boehringer Ingelheim GmbH, H1 2012 169
F. Hoffmann-La Roche Ltd., H1 2012 170
Kyowa Hakko Kirin Co., Ltd., H1 2012 171
Abbott Laboratories, H1 2012 172
Biogen Idec Inc., H1 2012 173
Shionogi & Co., Ltd., H1 2012 174
Amgen Inc., H1 2012 175
Sanofi-Aventis, H1 2012 176
Adherex Technologies Inc., H1 2012 177
AstraZeneca PLC, H1 2012 178
Eli Lilly and Company, H1 2012 179
GlaxoSmithKline plc, H1 2012 180
Mebiopharm Co., Ltd., H1 2012 423
IkerChem S.L., H1 2012 424
Agennix AG, H1 2012 425
ImQuest Life Sciences, H1 2012 426
Assessment by Monotherapy Products, H1 2012 427
Assessment by Combination Products, H1 2012 428
Assessment by Stage and Route of Administration, H1 2012 431
Assessment by Molecule Type, H1 2012 434
Solid Tumor Therapeutics – Drug Profile Updates 463
Solid Tumor Therapeutics – Discontinued Products 465
Solid Tumor Therapeutics – Dormant Products 479
List of Figures
Number of Products under Development for Solid Tumor, H1 2012 24
Products under Development for Solid Tumor – Comparative Analysis, H1 2012 25
Products under Development by Companies, H1 2012 26
Products under Investigation by Universities/Institutes, H1 2012 47
Late Stage Products, H1 2012 60
Mid Clinical Stage Products, H1 2012 61
Early Clinical Stage Products, H1 2012 62
Discovery and Pre-Clinical Stage Products, H1 2012 63
Assessment by Monotherapy Products, H1 2012 427
Assessment by Combination Products, H1 2012 428
Assessment by Route of Administration, H1 2012 429
Assessment by Stage and Route of Administration, H1 2012 430
Assessment by Molecule Type, H1 2012 432
Assessment by Stage and Molecule Type, H1 2012 433
[Tabellenverzeichnis ausblenden]